Back to top
more

Amedisys (AMED)

(Delayed Data from NSDQ)

$100.98 USD

100.98
592,706

+0.03 (0.03%)

Updated Aug 13, 2025 04:00 PM ET

After-Market: $100.98 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (34 out of 245)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

3 Reasons Why Growth Investors Shouldn't Overlook Amedisys (AMED)

by Zacks Equity Research

Amedisys (AMED) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Equity Research

Intersect ENT Rides on Innovation Amid Pricing Concerns

by Zacks Equity Research

The SINUVA business line of Intersect ENT (XENT) makes a quick and remarkable progress with market access and field force balance.

Zacks Equity Research

HMS Holdings Acquires VitreosHealth, Boosts PHM Solution Set

by Zacks Equity Research

HMS Holdings (HMSY) can leverage VitreosHealth's prescriptive health insights that will enhance its growing and lucrative PHM suite.

Zacks Equity Research

Here's Why You Should Retain OPKO Health (OPK) Stock For Now

by Zacks Equity Research

OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and solid R&D focus. However, operating losses remain a woe.

Zacks Equity Research

Medtronic Collaborates With Novo Nordisk for Diabetes Care

by Zacks Equity Research

This collaboration is expected to boost Medtronic's (MDT) diabetes management portfolio.

Sumit Singh headshot

Add These 5 Stocks With Impressive Interest Coverage Ratio

by Sumit Singh

Interest coverage ratio is used to determine how effectively a company can pay the interest charged on its debt.

Zacks Equity Research

DVA vs. AMED: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

DVA vs. AMED: Which Stock Is the Better Value Option?

Zacks Equity Research

BioSig Technologies-Mayo Clinic Ink Electrophysiology Deal

by Zacks Equity Research

This collaboration is expected to bolster BioSig's (BSGM) commitment toward offering higher quality patient care by introducing innovative technological solutions to medicine.

Zacks Equity Research

Here's Why You Should Hold on to Ecolab (ECL) Stock Now

by Zacks Equity Research

Ecolab (ECL) continues to gain from robust product portfolio and strong international presence. However, forex remains a woe.

Zacks Equity Research

Bruker (BRKR) Introduces the nanoIR3-s Broadband System

by Zacks Equity Research

The launch of the FTIR spectroscopy system complements Bruker's (BRKR) target to boost its portfolio of nanoIR products.

Zacks Equity Research

Integra Buys Rebound Therapeutics to Boost Neurosurgery Line

by Zacks Equity Research

Integra (IART) believes, Rebound's MIS technological arm will widen its neurosurgical pipeline within Codman Specialty Surgical space.

Zacks Equity Research

Medtronic's (MDT) MiniMed 670G Gains German Reimbursement

by Zacks Equity Research

Medtronic's (MDT) MiniMed 670G is witnessing a solid uptake in the United States ever since its launch last year.

Zacks Equity Research

Medtronic's (MDT) IN.PACT AV Access Study Results Bode Well

by Zacks Equity Research

The results of the study will prove to be a major stride for Medtronic (MDT) to treat patient suffering from renal diseases.

Zacks Equity Research

Here's Why You Should Invest in Intuitive Surgical (ISRG) Now

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to benefit from da Vinci surgical system, strong global foothold and solid recurring revenue base.

Zacks Equity Research

Masimo (MASI) Boosts O3 Platform With Three New Indices

by Zacks Equity Research

Masimo (MASI) announced the development of three additional indices for O3 Regional Oximetry, thereby improving the O3 platform.

Zacks Equity Research

Here's Why You Should Retain NextGen Healthcare Stock Now

by Zacks Equity Research

NextGen Healthcare (NXGN) is gaining traction from the U.S. RCM market and the growing EHR market. However, margin pressure remains a concern.

Zacks Equity Research

Here's Why You Should Invest in Amedisys (AMED) Right Now

by Zacks Equity Research

Amedisys (AMED) is currently enjoying investors' confidence, thanks to solid prospects.

Zacks Equity Research

Here's Why You Should Invest in Integer Holdings (ITGR) Now

by Zacks Equity Research

Integer Holdings (ITGR) continues to benefit from portfolio management, strong foothold in the broader MedTech space and rising Non-Medical sales.

Zacks Equity Research

Masimo (MASI) Introduces Pathway, Boosts Patient Monitoring

by Zacks Equity Research

Masimo's (MASI) new feature, Pathway, is likely to help clinicians simplify their workflow associated with newborn resuscitation, thereby improving patient monitoring.

Zacks Equity Research

Has Amedisys (AMED) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (AMED) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Here's Why You Should Hold on to Hill-Rom (HRC) Stock Now

by Zacks Equity Research

Investors' optimism continues to be high on solid prospects of Hill-Rom Holdings (HRC).

Zacks Equity Research

Here's Why You Should Hold on to DexCom (DXCM) Stock Now

by Zacks Equity Research

DexCom (DXCM) continues to benefit from growing glucose monitoring market, strategic buyouts and strong international presence. However, margin contraction remains a woe.

Zacks Equity Research

Here's Why You Should Consider Betting on CONMED Stock Now

by Zacks Equity Research

CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and persistent focus on R&D.

Zacks Equity Research

Here's Why You Should Retain PerkinElmer (PKI) Stock Now

by Zacks Equity Research

PerkinElmer (PKI) is gaining steadily from core Diagnostics segment, prudent acquisitions and margin expansion. However, forex volatility remains a concern.

Zacks Equity Research

Here's Why You Should Invest in Surmodics (SRDX) Stock Now

by Zacks Equity Research

Surmodics (SRDX) is gaining from consistent growth In Vitro Diagnostics (IVD) unit and persistent efforts to boost R&D functionalities.